Related references
Note: Only part of the references are listed.Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Impact of Galectins in Resistance to Anticancer Therapies
Pilar Navarro et al.
CLINICAL CANCER RESEARCH (2020)
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem et al.
ONCOLOGIST (2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
ACE: absolute copy number estimation from low-coverage whole-genome sequencing data
Jos B. Poell et al.
BIOINFORMATICS (2019)
Multicenter, Randomized, Double-Blind Phase 2 Trial of FOLFIRI With Regorafenib or Placebo as Second-Line Therapy for Metastatic Colorectal Cancer
Hanna K. Sanoff et al.
CANCER (2018)
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab
Erik van Dijk et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6 alpha-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study
Bianca Posocco et al.
PLOS ONE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
Emil ter Veer et al.
CANCER AND METASTASIS REVIEWS (2016)
Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer
Hiroshi Nokihara et al.
CLINICAL THERAPEUTICS (2016)
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir et al.
LANCET ONCOLOGY (2016)
Methylation-dependent regulation of HIF-1 alpha stability restricts retinal and tumour angiogenesis
Yunho Kim et al.
NATURE COMMUNICATIONS (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
Galectin expression in cancer diagnosis and prognosis: A systematic review
Victor L. Thijssen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
K. Shitara et al.
BRITISH JOURNAL OF CANCER (2014)
Circulating galectins-2,-4 and-8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis
C. Chen et al.
BRITISH JOURNAL OF CANCER (2014)
Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
Diego O. Croci et al.
CELL (2014)
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly
Ilari Scheinin et al.
GENOME RESEARCH (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2013)
Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization
Zhi-Zhou Shi et al.
CLINICAL CANCER RESEARCH (2013)
Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
Sandra Heskamp et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Saroj Niraula et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer A Phase II Study from the Hoosier Oncology Group
Jordan M. Schmitt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer
Shioto Suzuki et al.
BMC CANCER (2010)
It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies
Ingrid A. Boere et al.
CANCER SCIENCE (2010)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation
Gabriel A. Rabinovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CGHcall: calling aberrations for array CGH tumor profiles
Mark A. van de Wiel et al.
BIOINFORMATICS (2007)
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
Michiya Kobayashi et al.
GASTRIC CANCER (2007)
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
Victor L. J. L. Thijssen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Vascular endothelial growth factor-D and its receptor VEGFR-3:: Two novel independent prognostic markers in gastric adenocarcinoma
S Jüttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
